In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.

Dr. Ramien explores the concept of disease modification in AD focusing on disease control, and the prevention or slowing of development of atopic comorbidities.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Amy Paller reviews a Japanese study showing that early proactive treatment of infant atopic dermatitis with topical corticosteroids reduced the incidence of food allergy but was also associated with decreased gains in height and weight.
Professors Bouaziz, Paller, and Irvine discuss the clinical burden of atopic dermatitis, the biomarkers of subclinical control, and evidence of potential disease modification in AD at EADV 2025.

Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.

In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients
Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.

Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.
Join Professor Vibeke Backer for a presentation on clinical remission in asthma and achieving remission with biologics for patients with uncontrolled asthma.

Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.